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Mammalian cells contain thousands of copies of mitochondrial DNA (mtDNA). At birth, these are thought to
be identical in most humans. Here, we use long read length ultra-deep resequencing-by-synthesis to interro-
gate regions of the mtDNA genome from related and unrelated individuals at unprecedented resolution. We
show that very low-level heteroplasmic variance is present in all tested healthy individuals, and is likely to be
due to both inherited and somatic single base substitutions. Using this approach, we demonstrate an in-
crease in mtDNA mutations in the skeletal muscle of patients with a proofreading-deficient mtDNA polymer-
ase g due to POLG mutations. In contrast, we show that OPA1 mutations, which indirectly affect mtDNA
maintenance, do not increase point mutation load. The demonstration of universal mtDNA heteroplasmy
has fundamental implications for our understanding of mtDNA inheritance and evolution. Ostensibly de
novo somatic mtDNA mutations, seen in mtDNA maintenance disorders and neurodegenerative disease
and aging, will partly be due to the clonal expansion of low-level inherited variants.
INTRODUCTION
Nucleated mammalian cells contain thousands of copies of the
mitochondrial genome. Until recently, it has been generally
accepted that, for the vast majority of humans, all mitochon-
drial DNA (mtDNA) molecules are identical at birth (homo-
plasmy) (1,2) However, recent work has shown that 25%
of healthy individuals inherit a mixture of wild-type and
variant mtDNA (heteroplasmy), which almost exclusively
involves the non-coding mtDNA D-loop (3). Even less fre-
quently, ,1 in 200 inherit a potentially pathogenic variant
of mtDNA in the coding region (4). Being exclusively mater-
nally inherited, mtDNA undergoes negligible recombination
manifested at the population level. As a result, homoplasmic
variation of mtDNA has played a key role in determining
population migrations on a global scale (5) and in the confi-
dent identification of biological samples in forensic medicine
(6). Heteroplasmic variants can confound the situation in
both circumstances.
MtDNA is highly mutable, with an estimated mutation rate
of at least 5–15 times that of the nuclear genome. This is
partly a result of proximity to the electron transport chain
that is the major intracellular source of oxidative free radicals,
and partly a result of the relatively limited mtDNA protection
and repair mechanisms (7). The high mutation rate contributes
to the high levels of mtDNA diversity and also the generation
of somatic mtDNA mutations with aging (8). Once present, the
intracellular level of both inherited and somatic mtDNA muta-
tions can change during life through the unequal partitioning
of mitochondrial genotypes, which can occur during cytokinesis
in dividing cells (vegetative segregation) or within a non-
dividing cell through the relaxed replication of mtDNA. An
increase in heteroplasmy is often referred to as ‘clonal expan-
sion’ that may be enhanced by a replicative advantage for
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specific mutation types (9). If deleterious mutations exceed a
critical threshold level within a cell, they can cause a biochem-
ical defect in the mitochondrial respiratory chain (10).
This often involves cytochrome c oxidase (COX), leads to
increased free radical production, a defect of ATP synthesis,
cell dysfunction and ultimately cell death (1). High percentage
levels of inherited mtDNA mutations cause multisystem mito-
chondrial diseases in 1 in 10 000 of the population (11), and
high percentage levels of somatic mutations have been
described in several age-associated degenerative diseases
and possibly contribute to the aging process (12). Understand-
ing the origin of mtDNA variants, therefore, has far-reaching
implications, with impact on medicine, human anthropology
and forensic science.
Although generally assumed that age-related mtDNA muta-
tions originate during life, it is equally plausible that some os-
tensibly somatic variants are actually inherited, but fall below
the detection threshold of previously applied technologies.
With the recent development of massively parallel sequencing,
it is now possible to definitively address this issue through
the detection of very low-level heteroplasmic variants. Recent
studies using whole mtDNA genome sequencing on the
Illumina GA/Solexa platforms have suggested that a single het-
eroplasmic variant can be detected in 25% of individuals
(3,13–15). However, the relatively conservative detection
thresholds (a minor allele frequency of .1.5–10%) used in
these studies mean that lower frequency variants were not
reported, despite the fact that, from first principles, most
somatic mtDNA variants will be expected to fall below this
level.
We, therefore, sought to improve the depth of resolution for
very low-frequency heteroplasmy by developing an amplicon-
based resequencing method on the Roche 454 GS FLX
platform. Despite the very great depth of coverage per base
position achieved in previous studies using other platforms
(3,13–15), the achievable lower limit of resolution for hetero-
plasmic mtDNA variants is pragmatically limited by the
‘noise’ generated principally during the sequencing reaction.
Amplicon resequencing on the 454 GS FLX platform has,
thus, become the method of choice for ultra-deep resequencing
(UDS) of mutants and quasi-species within other small
genomes, for example viruses (16) and bacteria (17), where
resolution in the 0.1–1% variant frequency range has been
described.
RESULTS
Developing a highly sensitive and specific method
of detecting very low-level mtDNA sequence variants
At the population level, MT-HV2 within the mtDNA non-
coding control region is observed to be more polymorphic
than the coding region (18). We, therefore, designed two
mtDNA amplicons to compare the base substitution rate
in two regions in different subjects: one in MT-HV2
(nt 162–455, 294 bp) and one in the coding region MT-CO3
(nt 9307–9591, 285 bp) (see Supplementary Material,
Table S1). As nuclear pseudogenes [nuclear mitochondrial
sequences (NumtS)] have the potential to confound deep rese-
quencing of mtDNA, we took a three-stage process to exclude
the possibility of this affecting our data. Firstly, we compared
our amplicon loci with published NumtS to determine the
extent to which they nested within these regions and the cor-
responding degree of sequence identity (19). Only one of the
NumtS had a high sequence identity with modern mtDNA
(.90%) and was predicted to lie within our MT-CO3 ampli-
con (Supplementary Material, Table S2). However, this
NumtS was still predicted to differ by six nucleotide substitu-
tions from modern mtDNA, which significantly exceeded the
number of variants ever seen on single reads within our
dataset. Secondly, we used Primer-BLAST analysis of each
amplicon primer pair (hg19 build), which showed no predicted
non-mtDNA PCR product generation (20). Finally, we
attempted to PCR amplify a product using genomic DNA
extracted from rho0 cells that contained no mtDNA, following
ethidium bromide-induced mtDNA depletion to directly
confirm our predictions and to look for unexpected NumtS
hits. No product was obtained with either amplicon primer
set, despite a strong band with a positive control (nuclear
gene primers). We, therefore, concluded that nuclear pseudo-
gene amplification was highly unlikely with the specific
primers that we designed to amplify MT-HV2 and MT-CO3.
In the 454 assay, the mean depth of coverage using these
primers was 8391 reads (range 4158–20 803).
Although commercially available lambda phage controls can
be used to estimate the level of background sequencing arti-
facts, differences in guanine-cytosine content of the cloned tem-
plates can influence the outcome. We, therefore, designed
several in-house controls to determine the level of background
noise using the 454 platform on mtDNA templates: (i) a nuclear
DNA amplicon in BRCA2 (NC_000013.10, 32907099–
32907295, 197 bp) was designed to compare the intrinsic prop-
erties of mtDNA and nuclear genomic DNA, (ii) a cloned
nuclear DNA template corresponding exactly to the BRCA2
amplicons was generated from genomic DNA and (iii) we
cloned mtDNA templates from exactly the same mtDNA
sequences (MT-HV2, MT-CO3). On this basis, any difference
in sequence variants between the cloned and genomic DNA
templates from the same individual is highly likely to reflect
‘biological’ sequence variants generated in vivo and not tech-
nical artifact arising from the sequencing process.
Being based on pyrosequencing, the base-calling errors on
the 454 platform are very largely dependent on poly-
mononucleotide tracts (21). As our goal was to maximize spe-
cificity in calling very low-level variants, we, therefore,
excluded these tracts from all of the analysis. We also intro-
duced a further quality-control step, requiring observed var-
iants to be present in both forward and reverse reads at
comparable frequencies. A 3-fold difference was permitted
to allow for the effects of a binomial sampling distribution
at very low variant levels.
Using this highly stringent approach, there were no variants
present at .0.2% heteroplasmy in any of the cloned or
genomic DNA templates (Fig. 1). This demonstrated the low
background noise level using the 454 UDS approach and indi-
cated that variants detected at .0.2% heteroplasmy are highly
likely to be generated in vivo and to be of biological origin.
Further validation of this approach came from repeated
experiments performed using the same 454 platform, but dif-
ferent chemistry (Titanium) and different amplicon generation
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primers. Duplicate experiments were performed on four
samples of genomic DNA. There was 100% consistency of
variant detection between runs, but 6% of the variants
present in the first run fell below the 0.2% threshold in the
second run. The heteroplasmy level range for these variants
in the second run was 0.12–0.19%, demonstrating that these
fell just outside our defined threshold for detection, but were
indeed present.
Frequency of very low-level mtDNA sequence variants
in healthy control subjects
Next, we studied genomic DNA extracted from whole blood
and the skeletal muscle from unrelated and related healthy
individuals at different ages. Demographic and genotypic
details of the subjects are shown in Supplementary Material,
Table S3. Detected mtDNA sequence variants are shown in
Supplementary Material, Table S4.
All of the healthy control subjects showed variants at
.0.2% heteroplasmy in both the blood and skeletal muscle
DNA samples at one or more base positions. These data indi-
cate that very low-level single-base heteroplasmy appears to
be a universal finding among different control subjects
(Fig. 2A and B). The total number of variant base positions
was the same in the blood and skeletal muscle samples, but
variants at higher percentage heteroplasmy levels (.2%)
were present only in the skeletal muscle of some individuals
(three of seven healthy subjects) and never seen in the
blood. Higher level variants (.2%) were only found in the
MT-HV2 amplicon.
Overall, the number of variants per base position was sig-
nificantly more common in the skeletal muscle than in the
blood (P ¼ 0.001), and this difference was greater for
MT-HV2 than MT-CO3 (P , 0.001). In addition, the number
of variants per base position was significantly greater in
MT-HV2 than MT-CO3 (P , 0.001). In summary, the greatest
frequency of very low-frequency variants was seen in the
MT-HV2 region, and both the greatest number of different var-
iants and the highest heteroplasmy levels were seen in the
skeletal muscle.
The frequency of very low-level variants in disorders
of mtDNA maintenance
We studied patients with inherited defects of POLG encoding
the sole mtDNA polymerase g, predicted to have error-prone
mtDNA replication ((22–24). For comparison, we also
studied subjects with defects of OPA1. Skeletal muscle biop-
sies from these individuals show an excess of cells containing
clonally amplified mtDNA somatic mutations; however,
unlike for POLG defects, the mechanism is believed to be in-
direct, mediated through defects in mitochondrial fission and
fusion, rather than by any direct effect on the polymerase
(25–27). Clinical details and pedigrees are shown in Supple-
mentary Material, Table S3 and Supplementary Material,
Figure S1.
First, we studied eight patients with a variety of POLG
mutations (A467T/A467T, A467T/G848S, A467T/W748S,
R627Q/W748S and R627Q/R1096H). In skeletal muscle biop-
sies, the overall burden of mtDNA variants was greater in
patients with POLG mutations when compared with healthy
control subjects, but only for MT-HV2, where the majority
of variants were seen (P ¼ 0.004) (Fig. 2A). The excess of
mtDNA variants was present across all levels of heteroplasmy,
and increased significantly with age (r ¼ 0.86, P ¼ 0.006),
suggestive of a time-dependent accumulation of low-level
somatic mutations. There was no significant correlation of mu-
tation burden with age in healthy controls (r ¼ 0.62, P ¼
0.14). Given that the mutational burden was significantly
greater at lower heteroplasmy levels in POLG when compared
with control subjects (for ,1% heteroplasmy level variants,
P ¼ 0.019), these findings imply that that the higher mutation-
al burden is primarily due to de novo somatic mutation in
POLG patients.
We, then, studied multiple tissues from patients with muta-
tions in OPA1 (M1fsX208, S545R, V294fsX667, R905X and
intron 8 and intron 15 splicing defects). In contrast to the
POLG patients, there was no significant increase in mutational
burden in OPA1 patients when compared with healthy controls
in either the blood or skeletal muscle for the MT-HV2 or
MT-CO3 amplicons (Fig. 2A and B). These findings argue
against an increased rate of de novo mutagenesis in patients
with OPA1 mutations, consistent with there being no direct
effect on the polymerase g and in keeping with previous sug-
gestions that accelerated clonal expansion of existing somatic
mutations is responsible for the cellular cytochrome c oxidase
defects (28). We studied the mutational burden in the skeletal
muscle of one subject on two occasions 10 years apart. Six het-
eroplasmic variants were detected in the first muscle sample of
this individual. All six variants were also detectable at
Figure 1. Resolution of ultra-deep sequencing-by-synthesis assay. Demonstra-
tion of very low levels of noise in negative controls after quality-control filter-
ing for poly-mononucleotide tracts and bidirectional validation of variants. An
amplicon was produced from cloned DNA for each mtDNA amplicon
(MT-HV2, MT-CO3) along with an autosomal amplicon (BRCA2) and a
clone. All negative controls showed minimal numbers of base positions with
any variants, and none at .0.2% heteroplasmy level, with no inherent differ-
ences between the different DNA templates.
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comparable levels in the follow-up muscle sample taken 10
years later, although two variants in the second sample fell
below the 0.2% threshold (0.17%, 0.06%). Overall, five variants
showed a decrease in heteroplasmy level and one showed an in-
crease over the 10 year period; however, the absolute changes
were small (Supplementary Material, Table S5).
Determining whether very low-level variants are
maternally inherited
Having identified low-level heteroplasmic mtDNA variants in
the different pedigrees, we, then, compared related and unre-
lated individuals to determine the extent to which the
mtDNA variants arose through maternal transmission or
somatic mutation. We focused on families with known
nuclear genetic defects associated with mtDNA maintenance
because of the larger number of variants available for scrutiny
(i.e. increased signal strength).
We compared 13 pairs of samples from 12 maternal first-
degree relatives, including one subject with repeated blood
and muscle samples taken 10 years apart. To determine the
background level of similarity between unrelated individuals,
we compared the same tissue between 79 different random
pairs of unrelated subjects. Out of 485 variants, 59 variants
were common in unrelated subjects (12%). In contrast, when
the analysis was restricted to first-degree maternal relatives,
25/63 variants were shared (40%, P, 0.001, Table 1). We
also compared the frequency of sharing between 13 pairs of
related individuals and 13 random pairs of unrelated controls.
This also repeatedly revealed a highly significant difference
(P , 0.001), adding further weight to our conclusions. On
average, 39% of variants in a given individual were shared
with their maternal relative. Interestingly, shared variants
in related subjects were principally seen in the skeletal
muscle mtDNA, where 17/24 variants were shared (71%),
compared with 50/395 variants shared in unrelated subjects
(13%, P , 0.001). In contrast, variant sharing in related sub-
jects was rather uncommon in the blood mtDNA, where 8/
39 variants were shared (21%) when compared with 9/90 var-
iants in unrelated subjects (10%, P ¼ 0.10).
These findings have two implications. First, some of the
more common MT-HV2 variants are present in the background
population at very low heteroplasmy levels. Second, 4-fold
more variants are family specific and are transmitted
between first-degree maternal relatives. Although it is not pos-
sible, without longitudinal study, to state exactly what propor-
tion of variants are due to somatic mutation, the data clearly
show that a large proportion appear to be inherited at very
low heteroplasmy levels.
DISCUSSION
Using amplicon-based UDS at unprecedented depth, we have
shown that detectable very low-frequency mtDNA variants
(0.2–2% heteroplasmy) are present in all tested healthy sub-
jects.
It is highly unlikely that nuclear pseudogene (NumtS) con-
tamination influenced our results for the following reasons:
Primer-BLAST analysis (hg19 build) failed to identify any
predicted non-mtDNA PCR products using our specific
MT-HV2 and MT-CO3 primers; we were unable to generate
a product from rho0 genomic DNA using these primers. More-
over, further evidence came from the post hoc analysis of in-
dividual sequence reads and scrutiny of all predicted nuclear
pseudogenes (Supplementary Material, Table S2) (19).
Based on this analysis, a minimum of six changes from the
mtDNA consensus sequence would be expected in a read
from a pseudogene with our MT-CO3 primers and 48
changes for the MT-HV2 primers. Read-by-read analysis
never identified this number of variants, so pseudogene con-
tamination is extremely unlikely in our dataset. We conclude,
therefore, that heteroplasmy is a universal finding in humans.
Figure 2. Very low-level heteroplasmic mtDNA variance was detected by ultra-deep amplicon resequencing. (A) Comparison of variants detected in the skeletal
muscle (skm) DNA within theMT-HV2 amplicon in different patient groups shows no difference between healthy control (n ¼ 7) and OPA1 (n ¼ 8) subjects, but
a significant excess of variance at all heteroplasmy levels in POLG subjects (n ¼ 8). (B) Comparison of variants detected in the blood DNA in healthy control
(n ¼ 7), POLG (n ¼ 4) and OPA1 (n ¼ 7) subjects shows that variants are present, but less common than in the skeletal muscle DNA with the absence of higher
level variants (.2% heteroplasmy) and no difference between patient groups.
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Although our approach does not allow us to state with absolute
certainty whether any one variant is inherited or a somatic mu-
tation, a comparison of maternal relatives shows substantial
sharing between first-degree relatives, and our findings, there-
fore, show that inherited variants make a significant contribu-
tion to the overall mutation load in any one individual.
None of the heteroplasmic variants detected were hap-
logroup defining or haplogroup specific. Twelve of 40 base
positions containing heteroplasmic variants are reported to
be polymorphic (.1% of reported sequences with variants)
at the population level (http://www.mtdb.igp.uu.se/). None of
the variants detected have been ascribed definite pathogenic
potential, although a single mutation at position m.9544 has
previously been associated with optic neuropathy. We also
examined whether variants detected had previously been
reported as somatic mutations. In our data, 21 of 31 control
region (MT-HV2) heteroplasmic variants were detected, and
2 of 9 coding region (MT-CO3) variants have previous been
reported as somatic variants (http://www.mitomap.org/
MITOMAP) (Supplementary Material, Table S4).
Using this approach, we also show that a disrupted mtDNA
polymerase g due to a POLG defect leads to increased levels
of mutations, and that these increase during life, mirroring
observations in POLG-deficient mice (29,30). In contrast, we
did not observe a correlation between age and mutation
burden in control subjects, whether in the blood or muscle.
This suggests that de novo mutagenesis throughout life is un-
likely to contribute significantly to the cellular COX defects
observed in healthy aged individuals. Rather, age-related
COX defects are more likely to be the result of clonal expan-
sions of mutations occurring during early life (31). This notion
has recently been demonstrated in aged colonic crypt cells,
where multimethod measurement of mtDNA mutation load
failed to demonstrate an age-dependent increase (32).
However, our observation of very low-frequency hetero-
plasmy transmission indicates that that many of these muta-
tions will be inherited down the maternal line. As a result,
all clonally expanded species need not be the result of
somatic mutation events in early life, and some could have
arisen from low-level inherited variants.
The changes in low-level heteroplasmy value between each
mother and offspring (Supplementary Material, Figure S1 and
Supplementary Material, Table S4) are relatively small when
compared with the shifts observed in patient pedigrees carry-
ing higher levels of pathogenic mutations (33). However,
this is consistent with the neutral drift theory (34) which pre-
dicts that the variance in the offspring heteroplasmy due to the
mtDNA bottleneck decreases as the mother’s mutation level
decreases. These are the first data to show the inheritance of
such low-level mtDNA mutations. The high rate of inheritance
of the low-level mutation in muscle (71%) may be surprising,
considering our expectations of the effect of the mtDNA inher-
itance bottleneck; however, two points should be considered
here. First, that muscle data is from only two sibling pairs
[subjects A-B and P-Q (Supplementary Material, Figure S1
and Supplementary Material, Table S4)]. Second, as noted
above, the neutral drift theory predicts that very low-level
mutations will have low variance in the offspring, making
them more likely to be preserved through the mtDNA inherit-
ance bottleneck.
The different patterns of mutation observed in the blood and
skeletal muscle are, at least in part, likely to be a consequence
of different rates of cell and mtDNA turnover between divid-
ing (blood) and post mitotic tissues. Rapid turnover of blood
cells can lead to the loss of mtDNA mutations during life,
either through selection against a particular mutation (35) or
simply by genetic drift (36). On the other hand, the loss of
mutations is much less likely in a post mitotic tissue such as
the skeletal muscle, where the replication of mtDNA can
lead to an increase in mutation load during life within individ-
ual cells and the tissue as a whole, even from very low levels
of heteroplasmy (31). Thus, it is plausible that an inherited
mutation is lost from the blood, but detected in the muscle,
explaining why some inherited mutations are more likely to
be detected in the muscle than in the blood.
It is intriguing that the frequency of low-level variants in
MT-HV2 is significantly greater than in MT-CO3 in healthy
control subjects (OR 3.3). Why should this be the case,
given that our UDS of cloned mtDNA showed no intrinsic
sequence-specific difference between the two templates?
One possible explanation is that much of the non-coding
D-loop heteroplasmy is actually inherited at a very low
level. Being a non-coding region, these substitutions
may be tolerated during transmission, unlike coding region
variants that undergo strong negative selection during trans-
mission (37).
Perhaps most importantly, we show here that next gener-
ation sequencing has the potential to reliably detect very
low levels of heteroplasmy, when a very stringent analytical
approach is employed. It is important to note that we did not
perform a head-to-head comparison of different next gener-
ation sequencing platforms, so it would be premature to con-
clude that the 454 approach is superior to other platforms.
However, using this method, we have gained novel insight
into mtDNA within individuals and within pedigrees. Pro-
spective studies in larger family-based cohorts will substanti-
ate these findings. However, given that mtDNA
heteroplasmy levels can change dramatically during life, and
Table 1. Extent of sharing of variants in 13 pairs of maternally related and 79 pairs of unrelated samples















17 7 70.8 50 345 12.7 ,0.0001
Blood 8 31 20.5 9 81 10.0 0.10
All samples 25 38 39.7 59 426 12.2 ,0.0001
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during maternal transmission, the finding of universal mtDNA
heteroplasmy has significant implications for our understand-
ing of mtDNA at the population, family and individual
level. If deleterious mutations are inherited, these have the po-
tential to accumulate within single cells during life and thus
contribute to neurodegenerative disease. Or, if they segregate
rapidly through the mtDNA bottleneck, they could lead to a
maternally inherited mitochondrial disorder. This places
greater emphasis on the importance of developing techniques
to prevent the transmission of mtDNA heteroplasmy and pre-




All subjects gave informed consent for participation in re-
search. Characteristics of patient and control samples are
shown in Supplementary Material, Table S3 and Supplemen-
tary Material, Figure S1.
Molecular analyses
Amplicon resequencing was performed on the Roche 454 GS
FLX platform. Two mtDNA amplicons were used: MT-HV2
(NC_012920, nt.162–455) and MT-CO3 (nt.9307–9591).
Confirmatory experiments on a subset of samples used the fol-
lowing amplicon positions: MT-HV2 (nt.109–483) and
MT-CO3 (nt.9304–9653). Full primer sequences are shown
in Supplementary Material, Table S1. Owing to the potential
of nuclear pseudogenes to confound deep resequencing
studies of mtDNA, we used BLAST to ensure that our
primers avoided these areas and confirmed this by lack of
amplification from mtDNA deplete rho0 DNA. Amplicon-
specific mtDNA clones comprised the following inserts in a
pGEM-T-easy vector (Promega): MT-HV2 clone (nt.16548–
771) and MT-CO3 clone (nt.9127–9661). Autosomal negative
control comprised amplicon BRCA2 (NC_000013.10,
32907099–32907295) and BRCA2 clone (32906828–
32907480). Amplicon generation PCR reactions were per-
formed in a 50 ml volume comprising: 1x buffer for KOD
Hot Start DNA Polymerase (Novagen), 1.5 mM MgSO4,
0.2 mM dNTPs, 0.3 mM primers, 1 U KOD Hot Start DNA
Polymerase (Novagen) and 100 ng DNA. Cycling conditions
were 958C for 2 min followed by 30 cycles of 958C for 20 s,
608C for 10 s and 708C for 4 s. EmPCR and bidirectional se-
quencing were performed according to the manufacturer’s
instructions (Roche 454).
Bioinformatic analyses
Base calling and alignment were performed using the algo-
rithm of PyroBayes and Mosaik. Subsequent analysis of var-
iants was performed using the custom R library flowgram.
To maximize specificity for very low-level variants, base posi-
tions within or immediately adjacent to poly-mononucleotide
tracts were excluded from analysis. Variant calls were then
validated by comparison of read directions.
Primer-BLAST (20) analysis to confirm complete specifi-
city of amplicon generation primer pairs was performed
using standard stringent parameters: human genome assembly
hg19, blast E value 30 000and unintended targets with ,6
mismatches were considered.
Statistical analyses
Comparison of proportions of base positions between groups
was done using the chi-squared test.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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